Skip to main content

Lewis Joins Illumina from BD, Shanahan Named to Life Technologies Board, Cellular Dynamics Bolsters Exec Team, and More

NEW YORK (GenomeWeb News) - Mark Lewis has been named senior VP of development at Illumina, a role in which he will be responsible for global product development efforts. Lewis came to Illumina from Becton Dickinson Biosciences, where he was an executive involved in business development, and he recently was VP of special order research products. He also was involved in genomics technology research, gene characterization and discovery, and disease profiling at Aeomecia, and he led genotyping and DNA sequencing research at Molecular Dynamics.
 

 
Life Technologies has tapped William Shanahan to join its board of directors. Shanahan is the former president of Colgate-Palmolive, a post he kept from 1992 to 2005, and he is currently on the board of directors at Visa and MSD Ignition.
 

 
23andMe has hired Sarah Imbach to take over the role of chief operating officer and Larry Tesler to be a product fellow. Imbach formerly was VP of revenue and customer operations, and she previously was a senior VP of customer service operations and fraud at PayPal.
 
Tesler has been VP of user experience and design and a research fellow at Yahoo, and he formerly was VP of shopping experience at Amazon.com.
 

 
Cellular Dynamics International has added three new faces to its executive team, naming Chris Kendrick-Parker as chief commercial officer; Emile Nuwaysir as chief operating officer; and David Snyder as chief financial officer.
 
Kendrick-Parker formerly was VP of global pharmaceutical business at Affymetrix, and he was involved in drug discovery at Amersham Pharmacia. Nuwaysir was senior VP of program management and business development and he was CTO at Roche NimbleGen, and a manager at NimbleGen Systems prior to the company’s acquisition by Roche. He served as a researcher at the National Human Genome Research Institute and the National Institute of Environmental Health Sciences, where he helped to establish the National Center for Toxicogenomics. Snyder was site VP and CFO for Roche NimbleGen, and he helped lead NimbleGen through its initial public offering.
 

 
Richard Schifreen has taken over as president and CEO of Platypus Technologies. He has served as VP of research products at Mirus Bio and prior to that he was director of technology and business development at Promega. Schifreen also is a former faculty member at the University of Wisconsin School of Medicine and Public Health and a member of the cardiovascular medicine advisory board.
 

 
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.